FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005082022> ?p ?o ?g. }

• W3005082022 endingPage "396" @default.
• W3005082022 startingPage "381" @default.
• W3005082022 abstract "Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis sativa, differentiating from Δ9-tetrahydrocannabinol (THC) for its non-intoxicating profile and its antianxiety/antipsychotic effects. CBD is a multi-target drug whose anti-convulsant properties are supposed to be independent of endocannabinoid receptor CB1 and might be related to several underlying mechanisms, such as antagonism on the orphan GPR55 receptor, regulation of adenosine tone, activation of 5HT1A receptors and modulation of calcium intracellular levels. CBD is a lipophilic compound with low oral bioavailability (6%) due to poor intestinal absorption and high first-pass metabolism. Its exposure parameters are greatly influenced by feeding status (ie, high fat-containing meals). It is mainly metabolized by cytochrome P 450 (CYP) 3A4 and 2C19, which it strongly inhibits. A proprietary formulation of highly purified, plant-derived CBD has been recently licensed as an adjunctive treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), while it is being currently investigated in tuberous sclerosis complex. The regulatory agencies' approval was granted based on four pivotal double-blind, placebo-controlled, randomized clinical trials (RCTs) on overall 154 DS patients and 396 LGS ones, receiving CBD 10 or 20 mg/kg/day BID as active treatment. The primary endpoint (reduction in monthly seizure frequency) was met by both CBD doses. Most patients reported adverse events (AEs), generally from mild to moderate and transient, which mainly consisted of somnolence, sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being documented only in subjects on concomitant valproate therapy. The interaction between CBD and clobazam, likely due to CYP2C19 inhibition, might contribute to some AEs, especially somnolence, but also to CBD clinical effectiveness. Cannabidivarin (CBDV), the propyl analogue of CBD, showed anti-convulsant properties in pre-clinical studies, but a plant-derived, purified proprietary formulation of CBDV recently failed the Phase II RCT in patients with uncontrolled focal seizures." @default.
• W3005082022 created "2020-02-14" @default.
• W3005082022 creator A5010585139 @default.
• W3005082022 creator A5032075817 @default.
• W3005082022 creator A5032211553 @default.
• W3005082022 creator A5057518682 @default.
• W3005082022 creator A5058692435 @default.
• W3005082022 creator A5064235403 @default.
• W3005082022 creator A5087512489 @default.
• W3005082022 date "2020-02-01" @default.
• W3005082022 modified "2023-10-14" @default.
• W3005082022 title "<p>Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects</p>" @default.
• W3005082022 cites W1166458116 @default.
• W3005082022 cites W1588607894 @default.
• W3005082022 cites W1742914638 @default.
• W3005082022 cites W1819429514 @default.
• W3005082022 cites W1865383866 @default.
• W3005082022 cites W1873975405 @default.
• W3005082022 cites W1928931031 @default.
• W3005082022 cites W1945751328 @default.
• W3005082022 cites W1995352070 @default.
• W3005082022 cites W2020181579 @default.
• W3005082022 cites W2025784392 @default.
• W3005082022 cites W2056188558 @default.
• W3005082022 cites W2066134510 @default.
• W3005082022 cites W2075894678 @default.
• W3005082022 cites W2099625177 @default.
• W3005082022 cites W2101643484 @default.
• W3005082022 cites W2118574612 @default.
• W3005082022 cites W2129406235 @default.
• W3005082022 cites W2148841660 @default.
• W3005082022 cites W2168111104 @default.
• W3005082022 cites W2211460847 @default.
• W3005082022 cites W2228258434 @default.
• W3005082022 cites W2265950683 @default.
• W3005082022 cites W2320064572 @default.
• W3005082022 cites W2333305255 @default.
• W3005082022 cites W2414143586 @default.
• W3005082022 cites W2467915117 @default.
• W3005082022 cites W2514926883 @default.
• W3005082022 cites W2528830630 @default.
• W3005082022 cites W2580388554 @default.
• W3005082022 cites W2592601290 @default.
• W3005082022 cites W2605210160 @default.
• W3005082022 cites W2610432544 @default.
• W3005082022 cites W2620218661 @default.
• W3005082022 cites W2732466654 @default.
• W3005082022 cites W2744115661 @default.
• W3005082022 cites W2747652906 @default.
• W3005082022 cites W2766851314 @default.
• W3005082022 cites W2781878766 @default.
• W3005082022 cites W2785059893 @default.
• W3005082022 cites W2791384105 @default.
• W3005082022 cites W2804921146 @default.
• W3005082022 cites W2846779511 @default.
• W3005082022 cites W2891640176 @default.
• W3005082022 cites W2897092465 @default.
• W3005082022 cites W2897667112 @default.
• W3005082022 cites W2898181423 @default.
• W3005082022 cites W2898642751 @default.
• W3005082022 cites W2898687486 @default.
• W3005082022 cites W2900038566 @default.
• W3005082022 cites W2905603477 @default.
• W3005082022 cites W2907562503 @default.
• W3005082022 cites W2914333425 @default.
• W3005082022 cites W2915210550 @default.
• W3005082022 cites W2924479049 @default.
• W3005082022 cites W2930559544 @default.
• W3005082022 cites W2942802808 @default.
• W3005082022 cites W2949300926 @default.
• W3005082022 cites W2951978959 @default.
• W3005082022 cites W2955396164 @default.
• W3005082022 cites W2964129888 @default.
• W3005082022 cites W2965627648 @default.
• W3005082022 cites W2965877292 @default.
• W3005082022 cites W2969537152 @default.
• W3005082022 cites W2979896320 @default.
• W3005082022 cites W2980764484 @default.
• W3005082022 cites W4235677889 @default.
• W3005082022 cites W4235803847 @default.
• W3005082022 cites W4245959395 @default.
• W3005082022 doi "https://doi.org/10.2147/ndt.s203782" @default.
• W3005082022 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7012327" @default.
• W3005082022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32103958" @default.
• W3005082022 hasPublicationYear "2020" @default.
• W3005082022 type Work @default.
• W3005082022 sameAs 3005082022 @default.
• W3005082022 citedByCount "44" @default.
• W3005082022 countsByYear W30050820222020 @default.
• W3005082022 countsByYear W30050820222021 @default.
• W3005082022 countsByYear W30050820222022 @default.
• W3005082022 countsByYear W30050820222023 @default.
• W3005082022 crossrefType "journal-article" @default.
• W3005082022 hasAuthorship W3005082022A5010585139 @default.
• W3005082022 hasAuthorship W3005082022A5032075817 @default.
• W3005082022 hasAuthorship W3005082022A5032211553 @default.
• W3005082022 hasAuthorship W3005082022A5057518682 @default.
• W3005082022 hasAuthorship W3005082022A5058692435 @default.

• next